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Introduction: One of the main issues in juvenile systemic lupus erythematosus (JSLE) patients
is  infection, such as tuberculosis (TB). Of note, SLE patients are susceptible to pulmonary and
extrapulmonary TB. However, to our knowledge, this contagious disease was rarely reported
in  pediatric lupus population, particularly diffuse or miliary TB. Therefore, from January 1983
to  December 2011, 5,635 patients were followed-up at our Pediatric Rheumatology Unit and
285  (5%) of them met the American College of Rheumatology classiﬁcation criteria for SLE.
Case reports: Four (1.4%) of our JSLE patients had disseminated TB and were described herein.
All  of them were female gender, received BCG vaccination and did not have a history of TB
household contact. The median of current age at TB diagnosis and the period between JSLE
and  TB diagnosis were 17 years old (range 14–20) and 5.5 years (range 2–7), respectively. All
patients developed miliary TB during the course of the disease. The median of SLE Disease
Activity Index 2000 (SLEDAI-2K) was 4 (2–16) and the patients were treated with immuno-
suppressive agents (glucocorticoid, azathioprine and/or intravenous cyclophosphamide).
Two of them presented sepsis and TB diagnosis was only established at autopsy, especially
with lungs, central nervous system and abdominal involvements. Anti-TB therapy (isoni-
azid, rifampicin and pyrazinamide) was indicated in the other two TB cases, however they
deceased.
Discussion: Miliary TB is a rare and severe opportunist infection in pediatric lupus popula-tion.  This study reinforces the importance of routine searches for TB in JSLE patients.
©  2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mails: clovis.silva@icr.usp.br, clovisaasilva@gmail.com (C.A. Silva).
http://dx.doi.org/10.1016/j.rbre.2014.04.007
2255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Tuberculose  miliar:  infecc¸ão  oportunista  grave  em  pacientes  com  lúpus
eritematoso  sistêmico  juvenil
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Lúpus eritematoso sistêmico
r  e  s  u  m  o
Introduc¸ão: Um dos principais problemas no lúpus eritematoso sistêmico juvenil (LESJ) é
a  infecc¸ão, como a tuberculose (TB). É importante observar que pacientes com LES são
suscetíveis à tuberculose pulmonar e extrapulmonar. No entanto, de acordo com o que se
sabe,  essa doenc¸a contagiosa é raramente relatada na populac¸ão pediátrica com lúpus, par-
ticularmente a TB difusa ou miliar. De janeiro de 1983 a dezembro de 2011, 5.635 pacientes
foram acompanhados na Unidade de Reumatologia Pediátrica; 285 deles (5%) preencheram
os  critérios de classiﬁcac¸ão para LES do American College of Rheumatology.
Relatos de caso: Quatro (1,4%) de nossos pacientes com LESJ tinham tuberculose disseminada
e  foram descritos neste estudo. Todos eram do sexo feminino, receberam a vacina BCG e
não  tinham história de contato domiciliar com a TB. A mediana da idade no momento
do diagnóstico da TB e o período entre os diagnósticos de LES e tuberculose foram de 17
anos (variac¸ão de 14 a 20) e 5,5 anos (variac¸ão de dois a sete), respectivamente. Todas as
pacientes desenvolveram tuberculose miliar durante o curso da doenc¸a. A mediana no SLE
Disease Activity Index 2000 (SLEDAI-2K) foi de 4 (2 a 16) e as pacientes foram tratadas com
agentes imunossupressores (glicocorticoides, azatioprina e/ou ciclofosfamida intravenosa).
Duas delas apresentaram sepse e o diagnóstico de tuberculose só foi determinado na necrop-
sia,  com envolvimento especialmente dos pulmões, do sistema nervoso central e do abdome.
A  terapia antituberculose (isoniazida, rifampicina e pirazinamida) foi indicada nos outros
dois casos de TB; porém, as pacientes foram a óbito.
Discussão: A TB miliar é uma infecc¸ão oportunista rara e grave na populac¸ão pediátrica com
lúpus. Este estudo reforc¸a a importância de pesquisas de rotina para TB em pacientes com
LESJ.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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nfections are very important issues in juvenile systemic lupus
rythematosus (JSLE) patients, such as tuberculosis (TB).1
his is an endemic chronic infectious disease2 and it is the
econd cause of death due to contagious diseases in the
orld.3
Of note, SLE patients have an increased susceptibility to
ulmonary and extrapulmonary TB,4–8 with a poor outcome.6
B has been especially described in adult active SLE patients
eceiving immunosuppressive agents,6 and may mimic  lupus
linical ﬁndings.7 To our knowledge, this transmissible disease
s rarely reported in pediatric lupus population, particularly
iffuse or miliary TB.4
Therefore, from January 1983 to December 2011, 5635
atients were followed-up at our service and 285 (5%) of
hem met  the American College of Rheumatology (ACR)9
lassiﬁcation criteria for SLE. Four (1.4%) of our JSLE
atients had diffuse TB. The TB diagnoses were per-
ormed from 1996 to 2009 and these were described herein.
his study was approved by the Local Ethics Commit-
ee of our University Hospital. The demographic data,
linical manifestations, disease activity and disease dam-
ge indexes, laboratory exams and therapeutic regimen
t miliary TB diagnosis in JSLE patients are described in
able 1. The median of current prednisone dose at TB diag-
osis was 30 mg/day (15–60) (Table 1).Case  reports
Case  1
A 20-year-old girl was diagnosed with SLE at 17 years and 11
months based on the following ACR classiﬁcation criteria:9
photosensitivity, ulcers of the oral mucosa, arthritis in knees,
psychosis, granular casts and immunologic tests: antinu-
clear antibody (ANA) 1:200, anti double-stranded DNA (anti-ds
DNA) 1:40 (normal cut-off <1:10) and anti-cardiolipin (ACL)
IgM 63 MPL (normal cut-off <10). Intradermal reaction puri-
ﬁed protein derivative (PPD) test was 0 mm.  The SLE Disease
Activity Index 2000 (SLEDAI-2K) was 22.10 She was treated
with prednisone (60 mg/day), chloroquine (250 mg/day) and
azathioprine (100 mg/day). During the next two years, she
received chloroquine (250 mg/day). At the age of 20 years,
she was on remission and was admitted to the emergency
department due to three days of severe acute abdominal pain,
fever and cutaneous vasculitis (tender nodules in the hands).
Pneumoperitoneum was diagnosed and she was promptly
submitted to laparotomy. Caecal perforation with intestinal
vasculitis was identiﬁed and ﬁxed by ileum-ascendant colon
anastomosis. The SLEDAI-2K10 was 16 and she was treated
with three pulses of intravenous methylprednisolone (1 g/day)
and metronidazole, followed by prednisone (60 mg/day). The
Systemic Lupus International Collaborating Clinics/American
College of Rheumatology - Damage Index (SLICC/ACR-DI)11
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Table 1 – Demographic data, clinical manifestations, disease activity, disease damage, laboratory exams and treatment at
miliary tuberculosis (TB) diagnosis in juvenile systemic lupus erythematosus (JSLE) patients.
Variables Cases
1 2 3 4
Demographic data
Age at TB diagnosis, years 20 19 15 14
Interval between JSLE onset and TB diagnosis, years 2 7 6 5
Gender F F F F
BCG vaccination + + + +
TB contact history −  − − −
TB clinical manifestations Peritonitis,
pneumonia,
coma,
papilledema,
brain  herniation
Cough, mental
confusion,
headache
Cough, sputum,
dyspnea, mental
confusion,
irritability
Cough, sputum,
dyspnea,
adenomegaly,
abdominal pain,
drowsiness,
stupor
Disease activity and damage at TB diagnosis
SLEDAI-2K 16 2 2 4
SLICC-ACR/DI 1 2 0 0
Laboratory exams at TB diagnosis
Hemoglobin, g/dL 11.8 10.5 7.8 10
Hematocrit, % 36 32 26.4 27.1
Leukocytes, cells/mm3 5500 6600 4100 8600
Lymphocytes, cells/mm3 502 600 451 6622
Platelets, cells/mm3 104,000 150,000 69,000 271,000
Urinalysis
Leukocytes/mL 200,000 10,000 4000 9000
Erythrocytes/mL 710,000 23,000 0 1000
Proteinuria, g/24 h 0.01 0.98 0.1 1.42
CRP, mg/L 159 39.6 156 38.8
PPD test, mm 0 0 15 15
Chest X-ray Diffuse inﬁltrate Diffuse inﬁltrate Diffuse inﬁltrate,
pleuritis
Cotton wool
spots inﬁltrate
MT isolation Peritoneum,
diffuse in
autopsy
Diffuse in
autopsy
Sputum, diffuse
in autopsy
Sputum
JSLE treatment at TB diagnosis (mg/day) PD (60) PD (30), AZA (100) PD (15), AZA
(100), CH (250)
PD  (30), CH (250)
TB treatment NP NP HRZ MDRTB HRZ
Outcome D D D D
BCG, bacillus Calmette-Guérin; LAP, lymphadenopathy; CRP, C-reactive protein; NP, not performed; MT, Mycobacterium tuberculosis; - negative; +
positive; PPD, intradermal reaction puriﬁed protein derivative; H, isoniazid; R, rifampicin; Z, pyrazinamide; PD, prednisone; AZA, azathioprine;
CH, chloroquine diphosphate; MDRTB, multi-drug resistant TB; S, survived; D, deceased.
10 µm
Fig. 1 – Isolation of Mycobacterium tuberculosis in lungs
(case 1).
Fig. 2 – Granulomatous inﬂamation and caseous necrosis
in spleen (case 1).
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Fig. 4 – Granulomatous inﬂamation and caseous necrosisr e v b r a s r e u m a t o l
as 1. Six days later, she developed pneumonia and sepsis and
as treated with ceftriaxone and vancomycin. After two days,
he had coma (Glasgow status 6) and bilateral papilledema
as observed. Urgent brain computed tomography demon-
trated brain herniation and she deceased. Ten days after her
eath, the TB diagnosis was established at autopsy ﬁndings
emonstrated miliary TB with granulomatous inﬂamation
nd caseous necrosis with acid-fast bacillus, and isolation
f Mycobacterium tuberculosis in meninges, lungs (Fig. 1), peri-
oneum, spleen (Fig. 2), ovary and fallopian tubes. The M.
uberculosis was also isolated in cerebrospinal ﬂuid culture
CSF) culture 15 days after death. Other data related to the
atient during the tuberculosis period are presented in are in
able 1.
ase  2
 19-year-old girl was diagnosed with SLE at 12 years accord-
ng to the following ACR classiﬁcation criteria:9 malar rash,
ucosal ulcers, pericarditis, proteinuria 6.3 g/24 h, ANA (1:560,
ense ﬁne speckled pattern), anti-ds DNA (1:160) and anti-
m antibodies. The PPD test was 0 mm and SLEDAI-2K was
6.10 Renal biopsy showed focal proliferative lupus nephritis.
he was treated with three pulses of intravenous methylpred-
isolone (1.0 g/day), prednisone (60 mg/day) and chloroquine
250 mg/day) in combination with seven monthly intravenous
yclophosphamide (IVCYC) (0.5–1.0 g/m2/month) doses fol-
owed by every 3 months doses for a period of 2.5 years.
uring the next 5 years, she was on remission. At the age
f 19, she developed vertebral lumbar fracture. Intradermal
eaction puriﬁed protein derivative (PPD) test was 0 mm and
iffuse inﬁltrate in the chest X-ray (Table 1). SLEDAI-2K10
as 12, SLICC/ACR-DI11 was 2 and she received prednisone
30 mg/day) and azathioprine 100 mg/day. At that moment,
umbar dual-energy X-ray absorptiometry (DXA) showed z-
core of −4 and she was treated with alendronate and
alcitonin. Neither fever nor weight loss was reported. Two
2000 µm
ig. 3 – Granulomatous inﬂamation and caseous necrosis
n lungs (case 2).in liver (case 2).
weeks later, she presented with intermittent mild cough, men-
tal confusion, headache and developed acute pneumonia and
sepsis, and deceased after one week, despite broad spec-
trum antibiotics therapy (ceftriaxone and vancomycin). The
TB diagnosis was established at autopsy and revealed acute
pneumonia with alveolar hemorrhage, miliary TB with gran-
ulomatous inﬂammation, containing caseous necrosis with
isolation of M.  tuberculosis in cultures of lungs (Fig. 3), lymph
nodes, spleen and liver (Fig. 4). M.  tuberculosis was not isolated
in spine.
Case  3
A 15-year-old girl was diagnosed with SLE at 9 years accord-
ing to the following ACR classiﬁcation criteria:9 arthritis in
knees, serositis (pleuritis and pericarditis), lymphopenia, pro-
teinuria 1.1 g/day, ANA (1:560, dense ﬁne speckled pattern),
anti-ds DNA (1:60), and ACL IgG (45 GPL) antibodies. The PPD
test was 0 mm.  The SLEDAI-2K10 was 18, including nephri-
tis descriptors. She was treated with prednisone (60 mg/day),
azathioprine (150 mg/day) and chloroquine (250 mg/day). Dur-
ing the next 6 years, the patient presented mild disease
activity and at the age of 15, she had cough, sputum and
dyspnea and chest X-ray showed diffuse lung inﬁltrates
with unilateral pleuritis. At that moment she was receiving
prednisone (15 mg/day), azathioprine (100 mg/day) and chloro-
quine (250 mg/day). No family history of TB was reported.
The TB diagnosis was established according to culture of
sputum with M. tuberculosis and PPD test of 15 mm.  The
SLEDAI-2K10 was 2 and SLICC/ACR-DI11 was 0. She was
treated with rifampicin, isoniazid and pirazinamide. One
week later, she developed abdominal pain and vomiting. The
aspartate aminotransferase (AST) was 939 IU/L (normal 5–26),
alanine aminotransferase (ALT) 215 IU/L (normal 19–44) and
gamma-glutamyl transpeptidase (GGT) 1582 g/dL (10–22). Due
to hepatotoxicity, the anti-TB therapy was suspended. There-
fore, another screening test was performed and after 10 days,
sputum culture showed multi-drug resistant M.  tuberculosis
(namely resistance to isoniazid and rifampicin) and she was
treated with ciproﬂoxacin, ethambutol and streptomycin, the
second line treatment presented to eradicate Mycobacterium
tuberculosis with lower liver toxicity. Three days later, she had
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Fig. 5 – Granulomatous inﬂamation and caseous necrosis
in lungs (case 3).
tis that is the most signiﬁcant adverse event of TB therapy.6mental confusion, irritability and deceased. The autopsy ﬁnd-
ings showed miliary TB with granulomatous inﬂammation,
caseous necrosis and isolation of M. tuberculosis in cultures
of lungs (Fig. 5), spleen, liver and bone marrow.
Case  4
A 14-year-old girl was diagnosed with SLE at 9 years according
to the following ACR classiﬁcation criteria:9 arthritis in knees,
mucosal ulcers, hemolytic anemia and lymphopenia, protein-
uria 1.5 g/24 h, granular urinary casts, ANA (1:240), anti-dsDNA
(1:160) antibodies and lupus anticoagulant. The PPD test was
0 mm.  The SLEDAI-2K10 was 16, including nephritis descrip-
tors. She was treated with intravenous methylprednisolone
pulses (1.0 g/day), prednisone (60 mg/day) and chloroquine
(250 mg/day). One month after this treatment, the protein-
uria reduced and we  did not perform renal biopsy. During the
next 5 years, the patient remained moderate disease activ-
ity and at the age of 14, she had cough, fever, diffuse and
severe abdominal pain, sputum and dyspnea with cotton-wool
spots inﬁltrate on chest X-ray, and disseminated adenomegaly.
No family history of TB was reported. At that time she was
under prednisone (30 mg/day) and chloroquine (250 mg/day).
The TB diagnosis was established according to sputum cul-
ture with Mycobacterium tuberculosis. SLEDAI-2K10 was 4 and
SLICC/ACR-DI11 was 0. She was treated with rifampicin, iso-
niazid and pirazinamide. Despite the anti-TB treatment, one
day later, she developed drowsiness, stupor, severe dyspnea
and respiratory insufﬁciency, requiring mechanic ventilation.
Five days later she died. Her parents did not give their consent
for an autopsy procedure.
Discussion
To our knowledge, this was the ﬁrst study that evaluated dis-
seminated TB in pediatric JSLE population, and showed that
miliary TB was a rare and severe opportunist infection in
patients under immunosuppressive therapy. These patients
were followed-up in only one of the tertiary Pediatric Univer-
sity Hospitals in a large city of Brazil. 0 1 6;5 6(3):274–279
Importantly, our 285 JSLE patients received the bacil-
lus Calmette-Guérin (BCG) vaccination at neonatal period,
as indicated in all Brazilian newborn. Since this infection
is prevalent in our country,2 these patients are routinely
assessed for tuberculosis according to TB household contact
history, undergo PPD test and chest X-ray before immuno-
suppressive treatment. Our cases probably presented new
primary TB infections, since the PPD test was 0 mm when
immunosuppressive therapies were performed.
Tuberculosis is a contagious disease in which the deﬁ-
nite diagnosis requires the identiﬁcation of M. tuberculosis, as
conﬁrmed in all of our cases. It is spread by expectoration
of airborne droplets of people with active disease which are
inhaled and lodged in the distal airways.3 Intrinsic immuno-
logical abnormalities in humoral and cellular functions may
contribute to this opportunistic infection in lupus patients.1
The reactivation of remote infection can be triggered
due to an immune system abnormalities,2 and immuno-
suppressive disorders are considered risk factors for this
disease, such as HIV infection, severe malnutrition2 and SLE
patients.4–8
This contagious disease in adult SLE patients is habitually
insidious and can range from latent disease and isolated respi-
ratory system involvement to extrapulmonar TB.4–7,12 Other
sites affected in TB lupus patients are the central nervous
system, lymphatic organs, peritoneum,12 genitourinary tract,
vertebral bodies, joints and soft tissues.4,6,7 Of note, tubercu-
losis, particularly in lungs and meninges, was rarely reported
in JSLE patients, as observed in our lupus population.4,12
Moreover, disseminated or miliary TB, which involves
many organs simultaneously,3 has been described during the
disease course, as observed herein. The prevalence of this
severe disease occurred in 0% to 15% of adult SLE patients
suffering from TB.4–7 Diffuse TB may resemble sepsis, as
evidenced in our cases, and may be underestimated in lupus
population due to the fact that various rheumatologic services
do not perform necropsy systematically.1
The extra-pulmonary TB may also be related to immuno-
suppressive drugs, especially glucocorticosteroid use,7 as
observed in our patients. Furthermore, JSLE clinical manifes-
tations may also mimic  pulmonary and disseminated TB.1
Therefore, tuberculosis ought to be investigated in active lupus
patients.
The treatment of this infectious disease includes at least
three bactericidal drugs (isoniazid, rifampicin and pyrazi-
namide), as administered in our adolescent patients. One
limitation of the present study was the retrospective design,
which included patients diagnosed with TB before 2009 and
treated with these three medications. Currently, the ﬁrst-
line four-drug therapy is recommended according to World
Healthy Organization guidelines.13 In Brazil, we  have been
using these guidelines, including isoniazid, rifampicin, pyraz-
inamide and ethambutol in children older than 9 years of age,
since 2010.14
However, despite treatment, disseminated TB may have
a fatal outcome. One of our JSLE patients had acute hepati-Additionally, she also presented with multi-drug resistant M.
tuberculosis (namely resistance to isoniazid and rifampicin),
thus leading to an unfavorable outcome.
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This study reinforces the importance of screening with
ew tests for TB diagnosis, such as QuantiFERON-TB Gold test
hich is an IFN- release assays, since PPD, the classic assay
or latent tuberculosis infection diagnose, has diminished
ccuracy in immunosuppressed patients. 15 Indeed, recently
 study showed that QuantiFERON-TB Gold assay seemed to
e a more  accurate test for the detection of latent tuberculosis
nfection compared to PPD test in SLE patients that received
CG vaccination and did not report TB contact history.16
In conclusion, miliary TB is a rare and severe opportunist
nfection in pediatric lupus population. This study reinforces
he importance of routine searches for TB in JSLE patients,
specially with lungs, central nervous system and abdominal
nvolvements. A multicenter JSLE registry study to evaluate the
isk factors associated with this important contagious disease
ill be performed in Brazilian population suffering from this
hronic disease.
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